Post-menopausal hormone replacement therapy and stroke risk.
This paper will review available data bearing on the relationship of post-menopausal hormone replacement therapy to the risk of first or recurrent ischaemic stroke. Although experimental data from both human and animal studies will be briefly mentioned, the bulk of evidence is from observational epidemiological studies. As such, the limitations of observational studies, particularly as applied to the health effects of post-menopausal hormone replacement therapy, will be emphasized. We conclude that there is no compelling consistent evidence that post-menopausal hormone replacement therapy either decreases or increases stroke risk. There are, however, reasons to be concerned that this therapy may contribute to stroke risk.
Kittner
S J
SJ
Department of Neurology, University of Maryland School of Medicine, Baltimore, USA.
Bousser
M G
MG
D000818:Animals; D001161:Arteriosclerosis / Q000453:epidemiology / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control; D015914:Estrogen Replacement Therapy / Q000009:adverse effects* / Q000379:methods; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D012307:Risk Factors; D015983:Selection Bias; D020521:Stroke / Q000139:chemically induced* / Q000453:epidemiology; D013927:Thrombosis / Q000139:chemically induced / Q000453:epidemiology